0.19
+0.0027(+1.47%)
Currency In USD
| Previous Close | 0.18 |
| Open | 0.21 |
| Day High | 0.22 |
| Day Low | 0.17 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.16 |
| Volume | 119.83M |
| Average Volume | 7.46M |
| Market Cap | 6.12M |
| PE | -0.07 |
| EPS | -2.78 |
| Moving Average 50 Days | 0.5 |
| Moving Average 200 Days | 1.04 |
| Change | 0 |
If you invested $1000 in Plus Therapeutics, Inc. (PSTV) 10 years ago, it would be worth $0 as of June 24, 2025 at a share price of $0.205. Whereas If you bought $1000 worth of Plus Therapeutics, Inc. (PSTV) shares 5 years ago, it would be worth $6.48 as of June 24, 2025 at a share price of $0.205.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
GlobeNewswire Inc.
12 hours ago
Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request to withdraw the related resale registration statement with the SEC HOUSTON, June 24, 2025 (GLOBE NEWSWIRE) -
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
GlobeNewswire Inc.
May 23, 2025 8:15 PM GMT
HOUSTON, May 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced it received a delinquency notification letter from Nasdaq on May 21, 2025, which indicated that the Company was not in compliance with
Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)
GlobeNewswire Inc.
May 14, 2025 11:30 AM GMT
Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate immune responses Updated ReSPECT data presented at the 2025 Nuclear Medicine and Neurooncolo